Compared with the single-agent treatment groups, the combination treatment group showed a more notable reduction in Akt/p-Akt and FOXMI protein expression, suggesting that combination therapy with UA and PTX significantly inhibits tumor growth in xenograft animal experiments and has anti-tumor potential in ESCC. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.